Former President Trump has announced plans to impose a 100% tariff on generic drugs beginning in August 2028. The stated intention behind this significant trade action is to incentivize the reshoring of pharmaceutical production to the United States. This policy aims to encourage domestic manufacturing of medications currently sourced from abroad. Experts predict the tariffs could substantially increase prescription drug costs for American consumers. The move represents a protectionist approach to the pharmaceutical industry, prioritizing local production over potentially cheaper imports. The administration believes bringing drug manufacturing home will bolster national security and create American jobs. This announcement is likely to face opposition from healthcare providers and those advocating for affordable medication access.